Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The new insulins].

G Krzentowski1

  • 1Service d'Endocrinologie, C.H.U. de Charleroi, Polyclinique de La Madeleine.

Revue Medicale De Bruxelles
|October 26, 2005
PubMed
Summary
This summary is machine-generated.

Modern insulin analogues improve glycemic control and reduce hypoglycemia risk in diabetes management. These advancements offer better quality of life for patients compared to conventional insulins.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The role of diabetes associations].

Revue medicale de Liege·2005
Same author

[Another look at the implications of the DCCT study].

Annales d'endocrinologie·2004
Same author

Factors predictive of nephropathy in DCCT Type 1 diabetic patients with good or poor metabolic control.

Diabetic medicine : a journal of the British Diabetic Association·2003
Same author

Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control.

Diabetes care·2001
Same author

High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry.

Diabetes care·2000
Same author

Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.

Obesity research·1996

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology

Context:

  • Insulin therapy is crucial for managing diabetes mellitus.
  • Conventional insulins have limitations in mimicking physiological insulin secretion.
  • Achieving optimal glycemic control while minimizing hypoglycemia is a significant clinical challenge.

Purpose:

  • To review the evolution of insulin therapy.
  • To compare the pharmacokinetic profiles of conventional insulins and modern insulin analogues.
  • To assess the impact of insulin analogues on metabolic control and hypoglycemia risk.

Summary:

  • Insulin discovery revolutionized diabetes care, but conventional insulins present challenges in achieving physiological secretion patterns.
  • Rapid-acting analogues (lispro, aspart, glulisine) offer quicker and shorter action.

Related Experiment Videos

  • Long-acting analogues (glargine, detemir) provide a peakless profile and reduced variability.
  • These analogues facilitate better glycemic control with a lower risk of hypoglycemia.

    • Impact:

    • Improved metabolic control in both type 1 and type 2 diabetes.
    • Reduced incidence of micro- and macrovascular complications.
    • Enhanced quality of life for individuals with diabetes.
    • Highlights the ongoing need for further advancements in insulin therapy.